pyrazines has been researched along with Libman-Sacks Disease in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akashi, K; Arinobu, Y; Ayano, M; Fukata, M; Higashioka, K; Horiuchi, T; Imabayashi, K; Kashiwado, Y; Kawano, S; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N; Saiki, C; Yokoyama, T | 1 |
| Altamirano-Lagos, MJ; Fernández-Fierro, A; Funes, SC; Gómez-Santander, F; Jara, EL; Kalergis, AM; Mackern-Oberti, JP; Pulgar-Sepúlveda, R; Rebolledo-Zelada, D; Ríos, M; Rivera-Perez, D; Roa, JC; Villarroel, A | 1 |
| Channick, R; Chin, K; Coghlan, G; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Gesheva, VV; Nikolova-Ganeva, KA; Todorov, TA; Vassilev, TL; Voll, RE | 1 |
| De Vita, S; Michieli, M; Quartuccio, L; Rupolo, M | 1 |
| Wang, Y; Zhang, Z; Zhou, W | 1 |
| Alexander, T; Burmester, GR; Cheng, Q; Hiepe, F; Hoyer, BF; Klotsche, J; Kühl, AA; Lorenz, HM; Radbruch, A; Rech, J; Rubbert-Roth, A; Sarfert, R; Schett, G; Taddeo, A; Voll, RE; Waka, A; Wiesener, M | 1 |
| Bulanov, N; Moiseev, S; Novikov, P; Shchegoleva, E | 1 |
| Amann, K; Kalden, JR; Manz, RA; Maseda, D; Meister, S; Moser, K; Neubert, K; Voll, RE; Weisel, F; Wiethe, C; Winkler, TH | 1 |
| Hiepe, F; Voll, R | 1 |
| Aull, MJ; Dadhania, D; Hartono, C; Kapur, S; Saal, S | 1 |
| Aries, PM; Fröhlich, K; Gross, WL; Holle, JU; Moosig, F | 1 |
| Anolik, JH; Barnard, J; Conley, T; Goldman, BI; Ichikawa, HT; Jiang, J; Kirk, CJ; Lee, S; Looney, RJ; Muchamuel, T; Nevarez, S; Owen, T | 1 |
| Baráth, S; Bíró, T; Griger, Z; Gyetvai, Á; Kovács, I; Sipka, S; Tarr, T; Tóth, BI; Zeher, M | 1 |
| Ma, Y; Pan, HF; Xu, WD; Ye, DQ | 1 |
1 review(s) available for pyrazines and Libman-Sacks Disease
| Article | Year |
|---|---|
[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Immunotherapy; Lupus Erythematosus, Systemic; Mice; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Treatment Outcome | 2009 |
2 trial(s) available for pyrazines and Libman-Sacks Disease
| Article | Year |
|---|---|
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Risk Assessment; Scleroderma, Systemic; Survival Analysis | 2017 |
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Topics: Administration, Intravenous; Adult; Antibodies; Boronic Acids; Bortezomib; Dexamethasone; DNA; Drug Therapy, Combination; Female; Germany; Humans; Interferon Type I; Lupus Erythematosus, Systemic; Male; Plasma Cells; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2015 |
12 other study(ies) available for pyrazines and Libman-Sacks Disease
| Article | Year |
|---|---|
Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
Topics: Acetamides; Adult; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Lupus Erythematosus, Systemic; Pulmonary Arterial Hypertension; Pyrazines; Quality of Life | 2022 |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.
Topics: Animals; Antibodies, Antinuclear; Cell Differentiation; Cells, Cultured; Dendritic Cells; Dexamethasone; Disease Models, Animal; Humans; Immune Tolerance; Immunotherapy, Adoptive; Kidney; Lupus Erythematosus, Systemic; Lymphocyte Activation; Mice; Mice, Inbred MRL lpr; Pyrazines; Pyrroles; Rosiglitazone; T-Lymphocytes, Regulatory | 2019 |
Targeted silencing of DNA-specific B cells combined with partial plasma cell depletion displays additive effects on delaying disease onset in lupus-prone mice.
Topics: Animals; Antibodies, Monoclonal; Autoantigens; B-Lymphocytes; Boronic Acids; Bortezomib; Cyclophosphamide; Disease Models, Animal; Disease Susceptibility; DNA; Female; Humans; Lupus Erythematosus, Systemic; Lymphocyte Depletion; Mice; Mice, Inbred MRL lpr; Peptide Fragments; Pyrazines; Receptors, IgG; Recombinant Fusion Proteins | 2013 |
Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus.
Topics: Aged; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lupus Erythematosus, Systemic; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2014 |
Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient.
Topics: Aged; Anemia, Hemolytic; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Boronic Acids; Bortezomib; Comorbidity; Female; Humans; Lupus Erythematosus, Systemic; Proteasome Inhibitors; Pyrazines; Rituximab; Treatment Failure; Treatment Outcome | 2015 |
Bortezomib in refractory ANCA-associated vasculitis: a new option?
Topics: Boronic Acids; Female; Humans; Lupus Erythematosus, Systemic; Male; Plasma Cells; Proteasome Inhibitors; Pyrazines | 2016 |
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
Topics: Animals; Boronic Acids; Bortezomib; Lupus Erythematosus, Systemic; Mice; Mice, Inbred BALB C; Mice, Inbred MRL lpr; Mice, Inbred NZB; Models, Immunological; Nephritis; Ovalbumin; Plasma Cells; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors | 2008 |
Modulation of antibody response in a sensitized patient with ongoing antibody-mediated injury.
Topics: ABO Blood-Group System; Adult; Boronic Acids; Bortezomib; Female; Histocompatibility Testing; HLA Antigens; HLA-DQ Antigens; HLA-DR Antigens; HLA-DRB4 Chains; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Diseases; Kidney Transplantation; Lupus Erythematosus, Systemic; Male; Protease Inhibitors; Pyrazines; Reoperation; Siblings; Tissue Donors; Treatment Failure | 2009 |
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Treatment Outcome | 2011 |
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
Topics: Animals; Antibody-Producing Cells; Autoantibodies; Boronic Acids; Bortezomib; Disease Progression; Humans; Interferon Type I; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Oligopeptides; Protease Inhibitors; Pyrazines | 2012 |
Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells.
Topics: Adult; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gene Expression; Humans; Isoenzymes; Jurkat Cells; Lupus Erythematosus, Systemic; Male; Middle Aged; Organ Specificity; Primary Cell Culture; Proteasome Inhibitors; Protein Kinase C; Protein Kinase C-delta; Protein Kinase C-epsilon; Protein Kinase C-theta; Pyrazines; T-Lymphocytes | 2012 |
New evidence for the role of proteasome inhibitors in systemic lupus erythematosus: comment on the article by Ichikawa et al.
Topics: Animals; Antibody-Producing Cells; Boronic Acids; Humans; Interferon Type I; Lupus Erythematosus, Systemic; Lupus Nephritis; Oligopeptides; Protease Inhibitors; Pyrazines | 2012 |